The most common genomic alterations in addition to KRAS occurred in TP53 (70.6%), CDKN2A (38.1%), and SMAD4 (25.4%), consistent with data from The Cancer Genome Atlas.21Fig. 1 shows the distribution of genomic alterations for KRAS G12R vs. non-G12R mutated cancers. This evidence concerns the gene KRAS and cancer.